DYAI Berita Valas

Dyadic Int'l Collaborates With France's BYoRNA To Produce Abundant, Low-Cost MRNA From C1-Cells

Biotechnology companies Dyadic International, Inc. (DYAI) and France's bYoRNA SAS announced Tuesday that they entered into a development and commercialization agreement to work on disruptive bio-production technologies that will help exploit the therapeutic potential of messenger RNA (mRNA).

RTTNews | 675 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.15495	GBPUSD	1.32538	AUDUSD	0.64638
USDJPY	148.095	USDCAD	1.37846	USDCHF	0.80697

Advertisement

DYAI Berita Valas

Dyadic Int'l Collaborates With France's BYoRNA To Produce Abundant, Low-Cost MRNA From C1-Cells